Finance Watch: Early VC Forecast Predicts Reduced Investment In 2023

Last Biopharma Mega-Round Was Early December

Private Company Edition: Pitchbook is out with an early look at its venture capital expectations for next year, showing continued interest in seed financings and fewer $100m-plus mega-rounds. Recent VC deals include a $75m series B financing for Alpha-9 Theranostics and $71.6m for A2 Biotherapeutics. 

Finance Watch Private Company
• Source: Shutterstock

It is too soon for the Pitchbook and National Venture Capital Association (NVCA) Venture Monitor report detailing fourth quarter 2022 VC investment, including a breakdown of biopharmaceutical fundraising in the US, but Pitchbook recently released its forecast for VC investment broadly across all industries in 2023, which mirrors trends taking place in recent years in the biopharma industry.

US venture capital investment across industries is expected to total $120bn-$130bn in 2023. That would be the lowest amount of...

More from Financing

More from Business

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.